Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Cells with reduced N-glycan variability for therapeutic protein production

Cells with a modified Golgi N-glycosylation pathway could be useful for producing proteins with improved therapeutic properties. The GlycoDelete platform shortens the Golgi N-glycosylation pathway in mammalian cells to decrease N-glycan variability in proteins. In engineered human embryonic kidney (HEK) cells producing granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2), the protein had activity comparable to that of GM-CSF produced in the same cell line without the GlycoDelete modifications. In GlycoDelete-engineered HEK cells producing an anti-CD20 IgG, the antibody had a lower clearance rate than anti-CD20 IgG generated in a cell line without the GlycoDelete modifications. Next steps could include using the GlycoDelete platform to generate additional therapeutic proteins and comparing their properties with the parent compound.

SciBX 7(20); doi:10.1038/scibx.2014.598
Published online May 22, 2014

Patent application filed; licensing status unavailable

Meuris, L. et al. Nat. Biotechnol.; published online April 20, 2014;
doi:10.1038/nbt.2885
Contact: Nico Callewaert, Flanders Institute for Biotechnology (VIB), Ghent, Belgium
e-mail:

nico.callewaert@irc.vib-ugent.be